These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 11188837)

  • 1. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
    Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
    N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interruption of prophylaxis for major opportunistic infections in HIV-infected patients receiving triple combination antiretroviral therapy.
    Jubault V; Pacanowski J; Rabian C; Viard JP
    Ann Med Interne (Paris); 2000 May; 151(3):163-8. PubMed ID: 10896967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group.
    Phair J; Muñoz A; Detels R; Kaslow R; Rinaldo C; Saah A
    N Engl J Med; 1990 Jan; 322(3):161-5. PubMed ID: 1967190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group.
    Girard PM; Landman R; Gaudebout C; Olivares R; Saimot AG; Jelazko P; Gaudebout C; Certain A; Boué F; Bouvet E
    N Engl J Med; 1993 May; 328(21):1514-20. PubMed ID: 8479488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
    Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
    N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
    Miro JM; Lopez JC; Podzamczer D; Peña JM; Alberdi JC; Martínez E; Domingo P; Cosin J; Claramonte X; Arribas JR; Santín M; Ribera E;
    Clin Infect Dis; 2006 Jul; 43(1):79-89. PubMed ID: 16758422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy.
    Green H; Hay P; Dunn DT; McCormack S;
    HIV Med; 2004 Jul; 5(4):278-83. PubMed ID: 15236617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.
    El-Sadr WM; Murphy RL; Yurik TM; Luskin-Hawk R; Cheung TW; Balfour HH; Eng R; Hooton TM; Kerkering TM; Schutz M; van der Horst C; Hafner R
    N Engl J Med; 1998 Dec; 339(26):1889-95. PubMed ID: 9862944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.
    Mussini C; Pezzotti P; Antinori A; Borghi V; Monforte Ad; Govoni A; De Luca A; Ammassari A; Mongiardo N; Cerri MC; Bedini A; Beltrami C; Ursitti MA; Bini T; Cossarizza A; Esposito R;
    Clin Infect Dis; 2003 Mar; 36(5):645-51. PubMed ID: 12594647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
    Schneider MM; Hoepelman AI; Eeftinck Schattenkerk JK; Nielsen TL; van der Graaf Y; Frissen JP; van der Ende IM; Kolsters AF; Borleffs JC
    N Engl J Med; 1992 Dec; 327(26):1836-41. PubMed ID: 1360145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
    Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
    N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Withdrawal of Pneumocystis carinii pneumonia prophylaxis in patients receiving efficacious combined antiretroviral treatment. Study of 85 cases].
    García Vázquez E; de Górgolas Hernández M; García Delgado R; Fernández Guerrero ML
    Med Clin (Barc); 1999 Jun; 113(3):89-90. PubMed ID: 10464742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
    Schürmann D; Bergmann F; Albrecht H; Padberg J; Wünsche T; Grünewald T; Schürmann M; Grobusch M; Vallée M; Ruf B; Suttorp N
    Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):353-61. PubMed ID: 12072919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.
    Bozzette SA; Finkelstein DM; Spector SA; Frame P; Powderly WG; He W; Phillips L; Craven D; van der Horst C; Feinberg J
    N Engl J Med; 1995 Mar; 332(11):693-9. PubMed ID: 7854375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
    N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV. European Collaborative Study Group.
    BMJ; 1994 Feb; 308(6926):437-40. PubMed ID: 7907246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.